In brief, our results showed that the inhibition of S100A7/cPLA2 signaling could increase the infiltration of proliferating and activated CD4+ and CD8+ TILs in breast TME and may mount an enhanced anti-tumor immune response against aggressive metastatic breast cancer cells. Here, CD8A is linked to breast cancer.